Health Care [ 4/12 ] | Pharmaceuticals [ 26/74 ]
NASDAQ | Common Stock
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.24 Increased by +17.24% | -0.30 Increased by +20.05% |
| Nov 12, 24 | -0.28 Increased by +33.33% | -0.32 Increased by +12.50% |
| Aug 5, 24 | -0.31 Decreased by -24.00% | -0.34 Increased by +8.82% |
| May 13, 24 | -0.30 Increased by +3.23% | -0.34 Increased by +11.76% |
| Mar 14, 24 | -0.29 Increased by 0.00% | -0.29 |
| Nov 14, 23 | -0.42 Increased by +4.55% | -0.31 Decreased by -35.48% |
| Aug 8, 23 | -0.25 Increased by +54.55% | -0.34 Increased by +26.47% |
| May 15, 23 | -0.31 Increased by +43.64% | -0.27 Decreased by -14.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -21.80 M Decreased by -3.71% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.95 M Increased by +26.28% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -22.74 M Decreased by -27.05% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -22.37 M Decreased by -3.93% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.32 M Increased by +N/A% | -21.02 M Decreased by -32.85% | Decreased by -1.59 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -29.77 M Decreased by -76.97% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -17.90 M Decreased by -28.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -21.53 M Decreased by -56.31% | Decreased by N/A% Decreased by N/A% |